- 全部删除
- 您的购物车当前为空
Imdevimab (REGN10987) 是一种人的单克隆抗体,靶向导致 COVID-19 的SARS-CoV-2病毒。Imdevimab 对 COVID-19 变种缺乏疗效。Imdevimab 可与Casirivimab 联合使用,有效降低病毒载量,改善病症。
Imdevimab (REGN10987) 是一种人的单克隆抗体,靶向导致 COVID-19 的SARS-CoV-2病毒。Imdevimab 对 COVID-19 变种缺乏疗效。Imdevimab 可与Casirivimab 联合使用,有效降低病毒载量,改善病症。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,900 | 2-4周 | |
5 mg | ¥ 7,550 | 2-4周 | |
10 mg | ¥ 12,000 | 2-4周 |
Imdevimab 相关产品
产品描述 | Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1]. |
CAS No. | 2415933-40-1 |
存储 | store at -80°C | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容